- Home
- CTO vs COGT Comparison
CTO vs COGT Comparison
Compare CTO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- COGT
- Stock Information
- Founded
- CTO 1902
- COGT 2014
- Country
- CTO United States
- COGT United States
- Employees
- CTO N/A
- COGT N/A
- Industry
- CTO Real Estate Investment Trusts
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- COGT Health Care
- Exchange
- CTO Nasdaq
- COGT Nasdaq
- Market Cap
- CTO 589.6M
- COGT 545.3M
- IPO Year
- CTO N/A
- COGT 2018
- Fundamental
- Price
- CTO $17.81
- COGT $4.81
- Analyst Decision
- CTO Strong Buy
- COGT Buy
- Analyst Count
- CTO 3
- COGT 7
- Target Price
- CTO $23.00
- COGT $14.00
- AVG Volume (30 Days)
- CTO 227.3K
- COGT 1.3M
- Earning Date
- CTO 05-01-2025
- COGT 05-06-2025
- Dividend Yield
- CTO 8.51%
- COGT N/A
- EPS Growth
- CTO N/A
- COGT N/A
- EPS
- CTO N/A
- COGT N/A
- Revenue
- CTO $132,203,000.00
- COGT N/A
- Revenue This Year
- CTO $18.87
- COGT N/A
- Revenue Next Year
- CTO $9.15
- COGT N/A
- P/E Ratio
- CTO N/A
- COGT N/A
- Revenue Growth
- CTO 17.48
- COGT N/A
- 52 Week Low
- CTO $16.12
- COGT $3.72
- 52 Week High
- CTO $21.15
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CTO 42.72
- COGT 44.64
- Support Level
- CTO $17.88
- COGT $4.55
- Resistance Level
- CTO $18.03
- COGT $5.89
- Average True Range (ATR)
- CTO 0.29
- COGT 0.38
- MACD
- CTO 0.00
- COGT 0.09
- Stochastic Oscillator
- CTO 21.59
- COGT 34.55
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.